Tuesday, November 17, 2026

Online pharmacy "MINAKARA" raises approximately 1 billion yen in total|Collaborative development of private drugs with pharmaceutical manufacturers

minacolor, operator of the online pharmacy "minacolor," has raised 300 million yen in funding to expand its business. The subscribers are Spiral Innovation Partners, Incubate Fund, STRIVE, Asahi Media Lab Ventures, and Kaigen Pharma.

This latest fundraising brings Minakara's total amount raised to 1 billion yen. Going forward, the company will work on the development of central pharmacies (collective dispensing and distribution facilities) for the era of online medical care, the planning and development of pharmaceuticals developed jointly with pharmaceutical manufacturers (private brand pharmaceuticals), and support for the D2C development, sales promotion, and marketing of pharmaceutical manufacturers themselves.

About minacolor

Service URL:https://minacolor.com/

minacolor is an online pharmacy where users can purchase medicines with correct knowledge. Just as in offline pharmacies, value is provided all the way from knowing the right medicine for one's symptoms from the information held by pharmacists and pharmacists, to purchasing via Internet payment (*1), and then to medication management.

The company currently offers 800 SKUs of products centered on medicines, including over-the-counter ("OTC") drugs and other private products developed independently with pharmaceutical manufacturers, and proposes the most appropriate medicine for the patient's symptoms.

They are popular with patients who are too sick to purchase medicines in stores and with those who are raising children and have difficulty going out.

What you can do with Minacara

  • examine Get pharmacist-supervised medical information
  • choose Choose the right drug for you from a wide range of OTC drugs
  • Buy Now Online purchase of OTC drugs
  • Consult with us Free chat consultation with a pharmacist

1 Each drug is sold in accordance with the regulations of the drug category.

Online Pharmacy" is Minacara's goal


Minakara operates with the mission of "delivering self-care that is right for each and every person. The self-care we want to deliver is attracting a great deal of national attention, as evidenced by the introduction of the self-medication tax system.

And it is medicines and pharmacists that play a major role in self-care, and as a first step, Minakara is working to resolve this issue.

In the current Japanese healthcare system, there are many cases in which people are required to take OTC drugs at their own discretion. A survey conducted by the Advertising Bureau of the Asahi Shimbun's Tokyo Head Office (*2) also found that 71.61 TP3T have a tendency to use OTC drugs as a way to deal with colds, stiff shoulders, and other physical ailments for which they can determine symptoms themselves.

In addition, due in part to the impact of the new coronavirus, the demand for online drug purchases continues to increase year after year (*3). On the other hand, there are challenges in getting patients to take their medications with the correct information due to the following issues.

・OTC drugs are being converted to e-commerce, and drugs are getting into patients' hands without pharmacist's advice.
As a result of the flood of information on the Internet, it is unclear which information is correct and which information matches.
As a result of advertising and promotional effects of drugs, people choose drugs based on their impressions rather than on their symptoms.


Minakara aims to solve these issues and create an online pharmacy that helps consumers obtain health with correct knowledge of both prescription and OTC drugs.

2 JSMI - What to do when you feel sick 2008
https://www.jsmi.jp/reserch/asahi/0803.pdf
※3 2018年から2019年にかけて0.2%EC化率が向上(出典:経済産業省)
https://www.meti.go.jp/policy/it_policy/statistics/outlook/r1_kohyoshiryo.pdf

Funding Background

With the lifting of the ban on online sales of first-line drugs in 2014 and the major legal reform trend of the self-medication tax system in 2018, online sales of pharmaceuticals have attracted a lot of attention.

In addition, Minacara has been developing and selling private brand drugs in collaboration with pharmaceutical manufacturers since 2018. Compared to the sale of existing products, private brands are more beneficial to both pharmaceutical manufacturers and patients in terms of enhanced after-sales support and the ability to utilize EC data.

The market background and the results of the current services provided have led to this fundraising. With the procured funds, the company will promote the recruitment of human resources and other activities to provide more people with opportunities to use the company as an online pharmacy in cooperation with many pharmaceutical manufacturers.

Funding Summary

Past funding underwriters are listed below.

  • incubate fund
  • STRIVE
  • Spiral Innovation Partners
  • AG Capital
  • Graduate School of Management, Globis University
  • Kaigen Pharma
  • Japan Medic
  • Chiba Dojo
  • Mr. Keisuke Honda, professional soccer player and private investor

Underwriter's Comment

Hiroshi Oka, Managing Partner, Spiral Innovation Partners
We believe that the environment surrounding healthcare and pharmaceuticals is undergoing rapid and irreversible changes, such as the Corona Disaster and the promotion of self-medication.
We are convinced that Minakara is at the center of this revolution and has the power to revolutionize the overall distribution of medicines, from manufacturing to delivery to consumers. I have high expectations for the drug distribution revolution that Minakara will bring about.

Shuzo Ueki, Associate, Spiral Innovation Partners
In Japan, where the birthrate is declining and the population is aging rapidly, reducing medical costs by promoting self-medication is an urgent issue.
We are convinced that MINAKARA, with its excellent members including Mr. Kina, can solve this issue by eliminating the asymmetry of information in the purchase of pharmaceuticals, and have decided to invest in the company.
By accelerating collaboration with the Seino Group, the Fund's anchor LP, we will contribute to the growth of Minakara's business and ultimately improve the patient experience by transforming pharmaceutical logistics.

Mr. Yusuke Murata, Managing Partner, Incubate Fund
In the past six months, the field of medicine and dispensing has changed dramatically, and social issues related to delivery methods and information asymmetry have become much more apparent.
We have been accompanying Minakara since its inception, and there has never been a more important time to question our existence than now, so we have once again made an additional investment.

Mr. Ryo Taneichi, Associate, Incubate Fund
We have seen the market grow since the ban on online sales of OTC drugs was lifted in 2013 through the efforts of Kenko.com and Rakuten, and we feel that Corona has greatly improved the importance of self-medication and opened up the market.
We will do our best to support Minacara's efforts to create an "online pharmacy" experience similar to that of a store pharmacy online.

Mr. Tatsuo Tsutsumi, Managing Partner, STRIVE
We invested in Minacara Kina as we did last time, hoping to work together to realize Minacara Kina's vision of implementing "the next standard for everyday medical care.
One of the challenges facing Japanese society is how to optimize the ever-increasing cost of medical care, and one solution lies in reforming routine medical care, which is exactly the direction in which Minakara is heading.
We look forward to Minakara's continued growth.

Ms. Natsumi Negishi, Partner, STRIVE
Minakara is a unique team with a mix of pharmacists and engineers, and we have witnessed their passion and speed from the time of investment.
The company has been developing data-driven pharmacy services and products on the strength of its ability to capture data on customer preferences and needs that are difficult to capture in real stores, and we expect that this procurement will further accelerate DX in the OTC drug industry.

Masami Yamada, Director of Investment, Asahi Media Lab Ventures
Minakara has been involved not only in the sale of over-the-counter drugs, but also in their manufacture and distribution, online provision of information, free consultation with pharmacists, and post-purchase support, with the aim of realizing a world where all patients can take the right medicine for their symptoms.

name of companyMinakara Corporation
EstablishmentNovember 2013
LocationSD Bldg. 4F, 3-18-3 Uchikanda, Chiyoda-ku, Tokyo 101-0047, Japan
representativeShinya Kina
Business OverviewOperation of online pharmacy "Minakara
uniform resouce locatorhttps://about.minacolor.com/

Inquiry form for pharmaceutical manufacturers and users:
voice@minacolor.co.jp
https://about.minacolor.com/contact/
PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
- Advertisment -
- Advertisment -

Featured

東芝のオープンイノベーション、協業検討に進む2社が決定 ダイナミックマッププラットフォームとArithmerを選定

ReGACY Innovation Group株式会社(東京都千代田区)は、企画・運営パートナーとして支援する株式会社東芝の「Toshiba OPEN INNOVATION PROGRAM 2026」で、協業検討に進む参加企業2社が決定したと発表した。7月に募集した共創プランの中から、ダイナミックマッププラットフォーム株式会社とArithmer株式会社を選定。両社は東芝グループの「Hybrid-3D LiDAR」と「気象データサービス」を活用し、物流・インフラ分野などでの新たなソリューション共創を目指す。12月中旬の成果発表会に向け、実証と事業性検証を進める。 本プログラムでは、2026年7月6日から7月26日まで参加企業を募集しており、応募のあった共創プランの中から、ダイナミックマッププラットフォーム株式会社、Arithmer株式会社の2社が選定されました。 両社は、東芝グループが保有する「Hybrid-3D LiDAR」および「気象データサービス」の技術・データを用いて、物流・インフラ分野やデータ活用領域における新たなビジネスソリューションの共創を目指します。 今後は、12月中旬に予定されている成果発表会に向けて実証や事業性検証を進めるとともに、事業化を見据えた協業の検討を加速していきます。

新潟日報社、オープンイノベーションプログラム2026ピッチ審査会で「三ツ目」「想ひ人」2社を選定

新潟日報社は8月4日、「新潟日報社 オープンイノベーションプログラム2026 ピッチ審査会」を開催した。Creww株式会社が提供する「Creww Growth」を活用し、5月15日から6月15日にかけて新潟県や社会が抱える課題解決に向けた協業アイデアを募集。応募61件の中から書類審査を通過した8社がピッチに参加し、審査の結果「三ツ目」(新潟県三条市)と「想ひ人」(東京都)の2社を選定した。今後は実証事業等を通じて事業化を進める予定。

【ヤマサキ × BeeInventor】高温下での過酷な作業環境から、データは命を守れるか——創業151年の工業炉建設会社とスマートヘルメット新興企業が挑む「熱中症ゼロ」の現場

明治8年創業の株式会社ヤマサキは、建設業界向けアクセラレータープログラム「ヤマサキ×オープンイノベーションプログラム2024」を通じて、スマートヘルメットを手がけるビーインベンターとのPoCを実施した。内部温度800度を超える製鉄炉の傍らで働く現場作業員の熱中症リスクをAIで早期検知するという挑戦は、今まさに第2フェーズへと移行しようとしている。プロジェクトリーダーの向井裕一氏と、BeeInventor(ビーインベンター)のNao SeoChon氏に話を伺った。

【ヤマサキ × CHAOSRU】「誰も知らない技術」を、誰もが体験できる価値へ——創業151年の工業炉建設会社とVRスタートアップが挑む、採用×認知の壁の壊し方

明治8年創業の株式会社ヤマサキは、製鉄に欠かせない築炉の技術を持ちながら、業界・企業の認知度の壁が採用の課題となっていた。この課題の突破口を探るべく参加したのが、『ヤマサキ×オープンイノベーションプログラム2024』だ。プログラムを通じて、VR・XR技術を核とする株式会社CHAOSRUとの協業をスタート。2025年7月から始まったPoC(実証実験)では、高校生向け採用説明会へのVR体験の導入により、ブース来訪者数に明らかな変化が生まれている。アクセラレータープログラムを通じたスタートアップとの協業で何が動き、何が見えてきたのか。株式会社ヤマサキのプロジェクトリーダー 田中敏彦氏と、CHAOSRU代表取締役の内藤薫氏に話を伺った。